Plain-English translation of NCT06320067 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
STAMPEDE2 is testing two new approaches to treating advanced prostate cancer that has spread to other parts of the body. The first approach uses 177Lu-PSMA-617, a radioactive medication that targets prostate cancer cells throughout the body. The second uses stereotactic ablative body radiotherapy (SABR), a focused radiation technique that targets cancer spread in specific areas. Both treatments are being tested alongside the standard hormone therapy and other drugs that patients typically receive for this type of cancer.
Currently, the standard treatment for advanced prostate cancer is hormone therapy combined with other medications, but doctors want to know whether adding one of these new treatments can help slow the cancer's spread and help people live longer.
You likely qualify if…
You likely don't qualify if…
If you join, you'll first start standard hormone therapy. Then you'll be randomly assigned by computer to either continue with standard treatment alone, or to add one of the two new treatments. You'll have regular scans and blood tests to monitor your cancer and watch for any side effects. Your doctor will check in with you throughout the trial and can stop your treatment at any time if side effects become serious or if you no longer wish to continue.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United Kingdom